Integer Holdings Corporation
ITGRHealthcareNASDAQMedical Devices · Last scanned Sep 7, 2026
Scan Results
Daily timeframeInteger Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. With a market capitalization of $4.30B, it sits in mid-cap territory. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Market Cap
$4.30B
Beta
0.61
P/E (TTM)
34.56
P/E (Fwd)
18.42
EPS (TTM)
$3.66
EPS (Fwd)
$6.87
ROE
7.5%
ROA
3.9%
Cash
$21.4M
Total Debt
$1.36B
Free CF
$107.7M
52W Change
19.1%
Annual Financials
Cash vs Debt
Where ITGR stands vs its 150-day and 200-day moving averages
As of the August 24, 2026 close, ITGR finished 35.19% above its 150-day moving average ($92.61) and 42.31% above its 200-day moving average ($87.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ITGR overbought or oversold?
At the August 24, 2026 close, ITGR's RSI(14) was 60.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Integer Holdings Corporation carries $1.36B in total debt against $21.4M in cash reserves — debt is roughly 63.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $107.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 7.5% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.9% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.33B (2022) to $1.85B (2025), reflecting a 39% increase over the period.
The relatively low beta of 0.61 suggests ITGR is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ITGR.